Robin Young, MBChB, PhD
Chemotherapy with doxorubicin and ifosfamide improved progression-free survival (PFS) and tumor response compared with doxorubicin alone in soft tissue sarcoma, but the combination may be best suited for young, fit patients, according to results published online in Acta Oncologica
The UPS subgroup had a higher response rate with combination chemotherapy (42.3%) than with doxorubicin (6.9%; OR, 9.90; 95% CI, 1.93-50.7) according to central pathology assessment. Tumor response did not differ significantly between treatment arms for liposarcoma, leiomyosarcoma, synovial sarcoma or “other” subgroups.
Analysis of OS by local pathology assessment showed no interaction between histological subgroup and treatment arm. As assessed by central pathology review, doxorubicin/ifosfamide was associated with improved OS in patients with UPS compared with single-agent doxorubicin (HR, 0.44; 95% CI, 0.26-0.79).
... to read the full story